Plain-English translation of NCT05844384 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study tests a new device called the Nanodropper that delivers smaller amounts of glaucoma medication through eyedrops. Researchers want to know if using this special device works just as well as regular eyedrops at lowering eye pressure over three months. You would try both the new device and regular drops during the study to compare how they work for you.
Many people with glaucoma have trouble using eyedrops correctly, and smaller doses might reduce side effects while still controlling eye pressure. This trial will help doctors understand if the new device is a helpful option for managing glaucoma.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at the start, then again at 1 month, 3 months, and 6 months. For the first three months, you'll either use the new Nanodropper device or continue with your regular eyedrops—then you'll switch to whichever one you didn't use first for the second three months. At each visit, doctors will check your eye pressure and ask you questions about any side effects and how easy the device or drops are to use.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Sponsor
59th Medical Wing
Collaborators
Nanodropper, Inc.
Enrollment target
~30 participants
Started
March 2022
Primary completion
March 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jose E Capo-Aponte, OD, PhD
59th Medical Wing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.